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Abstract This review provides a short account of carbohydrate derivatives of an important natural drug, morphine, along
with their comparative efficacies as anesthetic agent. Sugar derivatives are found to have more prospect as anesthetic drug
than morphine itself owing to their enhanced bioavailability. Synthetic schemes of these sugar derivatives and information
on related patents are also included in this manuscript.
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1 Introduction
Morphine (1) is a natural product occurring in the opium
poppy Papaver somniferous and was first isolated in 1803 by
the German pharmacist Friedrich Wilhelm Sertu¨rner, who
named it ‘‘morphium,’’ derived from ‘‘Morpheus’’—the
Greek God of Dreams [1]. This natural product has been
used as the most important pain killer over many decades (or
centuries as opium) and it remains the most useful choice for
treatment of moderate to severe pain, either acute or chronic
[2, 3]. The pharmacological properties observed for mor-
phine, including analgesia, respiratory depression, and in-
hibition of gastrointestinal transit, are mediated by opioid
receptors [4]. However, its use as analgesic drug has not
been somuch explored owing to its limited bioavailability as
well as its pronounced toxicity. Therefore, it is of huge urge
of scientific communities for searching morphine deriva-
tives having greater bioavailability and of low toxicity so as
to develop promising analgesic drugs. Thus structural
modification (semi-synthesis) of morphine (1) is very much
significant in this context.
Glycosylation of natural products in some cases is con-
sidered as an effective structural modification responsible for
enhancing hydrophilicity of the molecules concerned—as a
result of which pharmacokinetic and/or pharmacodynamic
properties may be improved, although literature survey
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reveals that drugs having sugar moiety have generally less
hydrophilicity compared to its non-sugar analogue. In some
cases, attachment of a glycosyl residue provides a new che-
mical entity (prodrug), which facilitates the drug delivery in a
more effective manner. It has been found that inclusion of
carbohydrate moieties in a drug may increase its bioavail-
ability and decrease toxicity. Therefore, sugar derivative of a
drugmay bemore effective in treating a disease in such cases.
We have attempted in thismanuscript to focus someway-outs
for searching new promising anesthetic drugs having mor-
phine skeleton by considering different carbohydrate
derivatives of morphine along with their comparative effica-
cies as anesthetic agent mentioning also the synthetic
schemes used for their synthesis.
2 Synthesis of Morphine Sugar Derivatives
In order to search better anesthetic agent, many sugar
derivatives of morphine (1) have been synthesized (Fig. 1).
In the following Table 1 a notable number of such sugar
derivatives have been presented and their synthetic
schemes have been discussed later on. A comparative
discussion of sugar derivatives as anesthetic agents has
been presented in the bioactivity section. Sugar derivatives
of morphine are presented in the following Table 1 and
corresponding synthetic schemes are given.
In 1995, Kovac and Rice [5] first reported the synthesis
of morphine-6-O-glucoside (2) from 3-O-acetylmorphine
(2a). The synthesis involves glucosilation to form a gly-
coside followed by debenzoylation and deacetylation.
Highest yields of glycoside 2 (about 91 %) were obtained
when 2,3,4,6-tetra-O-benzoyl-a-D-glucopyranosyl bromide
is used a glycosyl donor, and condensation was promoted
with silver triflate. Following the same procedures another
sugar derivative, morphine-6-O-galactoside (3) was pre-
pared (Scheme 1) [5, 6].
The morphine-6-a-O-rhamnoside (4) was synthesized
by direct coupling of rhamnopyranose a-tetraacetate to



















































































Morphine-6-O-glucoside (2) Morphine-6-O-galactoside (3)
Morphine-6- -O-rhamnoside (4)
Demethyl 2,3-unsaturated analogue 




                (5, M6Man)
+
Codeine-6-O-glucuronide (6, C6G)
Morphine-6-O-glucuronide (7, M6G) Morphine-3-O-glucuronide (8, M3G)
+
Fig. 1 Morphine (1) and its sugar derivatives



































































































4-Deoxymorphine-6-glucuronide (10) Morphine-6-O-ribose analogue (11) 4,5-Unsaturated analogue of M6G (12)
Nalorphine-6-O-glucuronide (14) Demethyl M6G (13) Morphine-N-acetic acid-6-glucuronide (15)
Morphine-6-O-carboxytetrahydro-
             pyranoside (18)
C5-Inverted analogue of M6G (17)






































25a: R1=H; R2=COOH (54%)
25b: R1=Me; R2=COOH (79%)
25c: R1=H; R2=CH2OH (59%)
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Fig. 1 continued
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base hydrolysis of the esters (Scheme 2) [6]. The com-
pound 4a was prepared by two phase acylation of morphine
with pivaloyl chloride under Schotten–Baumann conditions
[7, 8]. The demethyl D2,3-unsaturated analogue of mor-
phine (9) was prepared by a Ferrier type reaction of 3-pi-
valoylmorphine (4a) with glycal, followed by ester
hydrolysis (Scheme 2) [6].
6-Morphinyl-a-O-mannopyranoside (5, M6Man) was
synthesized by Arsequell et al. [9] starting from 3-O-
acetylmorphine (2a) applying two procedures. In first pro-
cedures 3-O-acetylmorphine (2a) [10] and 1-trichloroace-
timidate-2,3,4,6-tetra-O-acetyl-mannopyranose are mixed
and stirred under an argon atmosphere at 0 C until the
addition of BF3Et2O complex. After 22 h of reaction at
room temperature, the mixture was diluted with methylene
chloride, washed with sodium bicarbonate, purified, and
deacetylated, yielding the 6-morphinyl-a-O-mannopyra-
noside (5) in a 57 % overall yield (Scheme 3). In the second
method (Koenigs–Knorr Method [11]) the mannoside (5)
was obtained in 34 % overall yield (Scheme 3) [9].
In 1968 Yoshimura et al. [12] developed a concise
method to prepare codeine-6-O-glucuronide (6, C6G) from
codeine (6a) by utilization of Koenigs–Knorr reaction [11]
(Scheme 4). Morphine-6-O-glucuronide (7, M6G) was also
synthesized similarly to that of compound 6 utilizing 3-O-
acetylmorphine (2a) as the starting material which was
prepared quantitatively by selective acetylation of mor-
phine according to the method of Welsh [10].
The highly active compound 7 was obtained from
morphine (1) by means of a series of reactions as depicted
in Scheme 5 [12]. Similarly synthesis of morphine-3-O-
glucuronide (8, M3G) was performed by the employment
of sodium hydroxide as the condensing agent in aqueous
acetone solution (Scheme 5). The method used was
essentially the same as those by Mannich [13] and by
Casparis and Bechert [14].
Table 1 Sugar derivatives of morphine (1)
Sl. no. Sugar derivatives of morphine (str. no.) Scheme no. References
1 Morphine-6-O-glucoside (2) Scheme 1 [5, 6]
2 Morphine-6-O-galactoside (3) Scheme 1 [5, 6]
3 Morphine-6-a-O-rhamnoside (4) Scheme 2 [6]
4 6-Morphinyl-a-O-mannopyranoside (5, M6Man) Scheme 3 [9]
5 Codeine-6-O-glucuronide (6, C6G) Scheme 4 [12]
6 Morphine-6-O-glucuronide (7, M6G) Scheme 5 [12]
7 Morphine-3-O-glucuronide (8, M3G) Scheme 5 [12]
8 Demethyl D2,3-unsaturated analogue of morphine (9) Scheme 2 [6]
9 4-Deoxymorphine-6-glucuronide (10) Scheme 6 [6]
10 Morphine-6-O-ribose analogue (11) Scheme 7 [6]
11 D4,5-Unsaturated analogue of M6G (12) Scheme 8 [6]
12 Demethyl M6G (13) Scheme 8 [6]
13 Nalorphine-6-O-glucuronide (14) Scheme 8 [6]
14 Morphine-N-acetic acid-6-glucuronide (15) Scheme 8 [6]
15 N-cyclopropylmethyl M6G (16) Scheme 8 [6]
16 C5-Inverted analogue of M6G (17) Scheme 9 [6]
17 Morphine-6-O-carboxytetrahydropyranoside (18) Scheme 9 [6]
18 7,8-Dihydro M6G (19) Scheme 10 [6]
19 7,8-Dihydro morphine-6-O-glucoside (20) Scheme 10 [6]
20 7,8-Dihydrodemethyl M6G (21) Scheme 10 [6]
21 Morphine-3-O-octylglucuronamide (22) Scheme 11 [17]
22 Morphine-3-O-glucuronamide (23) Scheme 11 [17]
23 Morphine-6-S-glucuronide (24a) Scheme 12 [4]
24 Codeine-6-S-glucuronide (24b) Scheme 12 [4]
25 Morphine-6-S-glucoside (24c) Scheme 12 [4]
26 Codeine-6-S-glucoside (24d) Scheme 12 [4]
27 Amide-linked C-b-glycopyranoside analogue of M6G (27) Scheme 13 [19]
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4-Deoxymorphine-6-glucuronide (10) was obtained
from b-tetraisobutyrate (10a) [15] by a sequence of
elimination using DBU followed by hydrogenation; the
major 5b-isomer (10b) was crystallised and was coupled to
4a followed by deprotection to give 4-deoxymorphine-6-
glucuronide (10) (Scheme 6) [6]. Morphine-6-O-ribose
analogue (11) was prepared via a sequence of tritylation of
D-ribose (11a) [16] followed by acylation and detritylation
to give intermediate 11b. Following oxidation to the























































(Same Procedures followed) 
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Scheme 2 Synthesis of morphine-6-a-O-rhamnoside (3) and demethyl D2,3-unsaturated analogue of morphine (9) [6]



















































6-morphinyl- -D-mannopyranoside (5, M6Man)
[7]























































Scheme 4 Synthesis of codeine-6-O-glucuronide (6, C6G) [12]
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sugar was coupled as an a/b-mixture to N-cyclopropyl
methyl M6G (16); subsequent deprotection gave morphine-
6-O-ribose analogue (11) as a single (b-) anomer
(Scheme 7) [6].
Stachulski and his group [6] accomplished the synthesis
of various types of analogues of morphine (1). The starting
compound 12a [15] underwent many series of reactions to
furnish D4,5-unsaturated analogues of M6G (12), demethyl
M6G (13), nalorphine-6-O-glucuronide (14), morphine-N-
acetic acid-6-glucuronide (15) and N-cyclopropylmethyl
M6G (16) as depicted in Scheme 8 [6]. The same research
group [6] also accomplished the synthesis of C5-inverted
analogue of M6G (17) and morphine-6-O-carboxytetrahy-
dropyranoside (18) from 3-pivaloyl morphine 4a
(Scheme 9). And also 7,8-dihydro analogues (19–21) of
M6G, morphine-6-O-glucoside and demethyl M6G were
obtained by hydrogenation of 7, 2 and 13, respectively
(Scheme 10); 20 was conveniently isolated as its succinate
salt, while 19 and 21 were kept in their zwitterionic forms
[6].
Salvatella and his group [17] have synthesized a lipo-
philic M3G analogue, morphine-3-O-octylglucuronamide
(22) (Scheme 11). The simplest route was to form an amide
bond between the carboxylic acid group on M3G (8) and a
primary linear alkyl amine. Accordingly, the whole pro-
cedure for morphine-3-O-octylglucuronamide (22) syn-
thesis started following a one-pot reaction method to
prepare M3G (8). This glycosidation reaction departed
from morphine (1) and methyl (2,3,4-tri-O-acetyl-a-D-



























































































Scheme 5 Synthesis of morphine-6-O-glucuronide (7, M6G) and morphine-3-O-glucuronide (8, M3G) [12]
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LiOH as promoter and base for the removal of acetyl
protecting groups [18]. In a second step, the coupling re-
action between the glucuronide M3G (8) and octylamine
was accomplished by means of the uronium salt HBTU [2-
(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hex-
afluoro-phosphate] afforded 40 % yield after crystallization
from acetone/water (Scheme 11) [17]. Similarly, mor-
phine-3-O-glucuronamide (23) was prepared from mor-
phine (1) and the corresponding acetylated glucuronamide
bromide derivative also using the LiOH method
(Scheme 11) [17].
A series of 6-b-thiosaccharide (25a–d) analogues of
morphine-6-glucuronide (7) and codeine-6-glucuronide
(6) were synthesized by MacDougall [4]. The starting
compounds for the preparation of the thiosaccharides
47a–f and 25a–d were 6-O-tosylmorphine 45a, 3-O-
acetyl-6-tosylmorphine 45b, and 3-O-tosylcodeine
45c [10]. The tosylates 45a–c were prepared in good
yield by the reaction of either 3-O-acetylmorphine or
codeine with p-toluenesulfonyl chloride in pyridine at
3 C overnight. The key step in the synthesis of
47a–f was the attachment of the thiosaccharide to the
phenanthrene nucleus by an SN2 displacement reaction
(Scheme 12) [4].
A eight-step synthesis of amide-linked C-b-glycopyra-
noside analogue of M6G (27) was achieved by MacDougall
and his group [19] using 3-triisopropylsilyl-6-b-aminomor-
phine and 2,3,4,6-tetra-O-benzyl-D-glucose (Scheme 13).
3 Biological Activities
There are three major types of opioid receptors: mu (l),
delta (d) and kappa (j). Morphine (1) is an agonist and
partial agonist of l and d opioid receptors, respectively
[20]. Opioid receptors are mainly localized in the limbic
system. They are involved in the control of emotion and
reward behaviors; the ascending and descending pain
pathways that include the different laminae layers of cor-
tex, thalamus, periaqueductal grey, midbrain median
raphae and the dorsal horn of the spinal cord; and specific
brain regions that are known to control locomotion, emesis,
cough and temperature [20]. Some pharmacological effects
associated with opioid receptor types are presented in
Table 2.
In human beings, morphine (1) is predominantly me-
tabolized by hepatic glucuronosyl transferases with the
addition of glucuronic acid at 3-O-position in the aromatic
ring or at 6-O position on the phenanthrene ring, furnishing
the morphine 3-O-glucuronide (8, M3G) and morphine
6-O-glucuronide (7, M6G), respectively [21, 22]. Ap-
proximately 10 % of morphine (1) is metabolized to M6G
(7) and 50 % to M3G (8) [23]. Many reports have disclosed
the very low affinity of 8 to l-opioid receptors [24] and, in
a small study in humans, it appeared to be devoid of sig-
nificant analgesic activity [25]. However, the analgesic
potency of 7 in animals with significantly reduced respi-











































Scheme 6 Synthesis of 4-deoxymorphine-6-glucuronide (10) [6]
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greater than that of morphine [26, 27]. It has been found
that the high potency of M6G (7) as an analgesic is me-
diated through opioid receptors [28]. These observations
are apparently controversial due to the polar properties of
7. Villesen et al. [29] studied pharmacokinetics of M6G (7)
on healthy volunteers and proposed that M6G is hydrolysed
to morphine 1 in the colon, which is then absorbed and
subsequently undergoes metabolism in the liver to mor-
phine-3-glucuronide (8, M3G) and M6G [29]. M6G (7) is
also able to penetrate the blood–brain barrier, although this
occurs in a lower extent when compared to morphine [30–
32]. Two possible mechanisms for this phenomenon have
been proposed. The first one lies on the active transport of
M6G across blood–brain barrier through a glucose trans-
porter. There is an evidence on modulation of M6G entry
into brain by membrane P-glycoprotein (Pgp) [33–35]. The
second hypothesis is based on partitioning experiments and
computer simulations and suggests that M6G molecules act
like ‘‘molecular chameleons’’ by adopting a confirmation
of lower polarity when passing the blood-brain barrier
(BBB) [36–38]. Research is going on only to include sugar
moiety at 6-position and to compare their anesthetic po-
tential with morphine in order to develop new improved
anesthetic drug. Therefore, limited reports are expected. In
summary, the reduction in side-effects and enhanced po-
tency observed for M6G make this morphine gly-
coderivative a promising drug candidate for the treatment
of cancer-related pain as well as a lead compound for
further development of new drugs.
Recently, non-glucuronic analogues (2–4 and 10–11) of
M6G were synthesized. Affinities of these morphine gly-



















































Scheme 7 Synthesis of morphine-6-O-ribose analogue (11) [6]
























4,5-Unsaturated analogue of M6G (12)
-Chloroethyl chloro-
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Scheme 8 Synthesis of D4,5-unsaturated analogue of M6G (12), demethyl M6G (13), Nalorphine-6-O-glucuronide (14), Morphine-N-acetic
acid-6-glucuronide (15) and N-cyclopropylmethyl M6G (16) [6]
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activities using the hotplate method were also described
[6]. This study shows that b-glucoside 2 was the only
compound with significant antinociceptive activity at doses
of 2 and 4 mg/kg, along with slightly higher affinity for l1
receptor. Then, the constant of receptor inhibition (ki) for
compound 2 was 0.28 nM whereas morphine (1) or M6G
(7) presented a ki of 0.78 and 1.5 nM, respectively. When
rhamnoside substitutes glucose (analogue 4) the ki for this
morphine glycoderivative towards l1 receptor becomes
0.17 nM. However, its antinociceptive activity is very low.
The galactoside 3 (ki = 1.2 nM) had similar l1 affinity to
morphine (1) and M6G (7), showing some antinociceptive
activity at 4 mg/kg and significant one at 8 mg/kg. All
glycoderivatives studied (2–4) presented affinity to l2 re-
ceptor similar to that for morphine. The analogues 10 and
11, which possess acid sugar residues, showed slightly
higher l1 affinity, but reduced antinociception when com-
pared with morphine (1) [6]. In general, Stachulski and
coworkers disclosed that modification of the carbohydrate
at 6-O-position of morphine promotes marked in vitro ef-
fects on binding to l opioid receptor subtypes l1 or l2 and
in vivo antinociceptive activity [6]. 6-morphinyl-a-D-
mannopyranoside (5) is found to have 100-fold higher
naloxone-reversible antinociception activity and twice as
long lasting compared to morphine (1) when administered
intraperitoneally to rats. Moreover, this compound 5 does
not produce tolerance and binds to rat l opioid receptors
with two fold affinities than morphine 1. It has been con-
cluded on the basis of NMR studies that differences of
activity between the derivative and its parent compound
M6G (7) might be related to their differing molecular dy-
namic behavior [9].
Although M6G (7) and some of its O-glycosides present
significantly greater analgesic potency than morphine (1),
the bioavailability of these compounds could be a problem
for a useful drug. For instance, the oral bioavailability of
M6G is only 11 % and improvement of chemical and
metabolic stability of M6G could possibly increase its ef-
fectiveness as a potential drug. Limited hydrophilicity has
been a major problem in most of the cases for morphine
sugar derivatives making obstacles to be used in clinic.
However, examples are known which are in Clinical trials
e.g. M6G is being developed by CeNeS (Cambridge, UK)
as a treatment for postoperative pain, and is currently un-
dergoing phase III trials in Europe, with phase III clinical
trials in the USA expected to commence in 2007 [39]. A
general strategy for improving in vivo metabolic stability
of glycoconjugates involves the replacement of glycosidic
oxygen atom by carbon, nitrogen, or sulfur atoms. Indeed,
MacDougall and coworkers have developed a new series of
sulfur (24a, 24b, 25a and 25c) and carbon (26 and 27)





































C5-inverted analogue of M6G (17)
44
Scheme 9 Synthesis of C5-inverted analogue of M6G (17) and Morphine-6-O-carboxytetrahydropyranoside (18) [6]
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some compounds with metabolic stability for sustained
pharmacological activity [4, 19]. Compounds 24a and 24b
were full l receptor agonists, whereas compounds 25a and
25c were only partial agonists. This finding indicates that
the presence of a hydrogen atom (as a hydrogen bound
donor) or a carboxyl group at C-60 in sugar moiety is not a
requirement for agonist activity of these analogues.
Moreover, analogue 27 and its deprotected sugar congener
26 were both l receptor selective [19]. Compound 27
(ki = 0.5 nM) presented an affinity to l opioid receptor
26-fold higher than that observed for M6G. Selectivities of
compound 27 for l versus d and l versus j receptors were
tenfold and 34-fold, respectively. Higher potency was also
observed for 26 (3.7-fold) in comparison with M6G.
Selectivity of compound 26 for l versus d and l versus j
receptors were 77-fold and 166-fold, respectively. This
compound showed slightly greater potency towards l re-
ceptor (2.5-fold) over M6G (8) when compared to
thiosaccharides 25a and 25c (around 1.6-fold) [19]. In
addition, compound 26 presented considerable metabolic
stability when assayed hepatic microsome preparations
from rat and monkey. No detectable loss of 26 was ob-
served during 90 min of system incubation. Compound 26
was also very stable at pH 2 or pH 7.4.
4 Related Patents on Morphine and its Sugar
Derivatives
About sixteen patents on morphine and its sugar deriva-
tives are available, which deal with isolation technique,
purification, synthesis of various sugar derivatives and
their analogues, evaluation of their anesthetic activity and
other pharmaceutical potentials. Such related patent in-
formation including all necessary agenda are presented in
Table 3.





























































Demethyl M6G (13) 7,8-dihydrodemethyl M6G (21)
Scheme 10 Synthesis of 7,8-dihydro M6G (19), 7,8-dihydro morphine-6-O-glucoside (20) and 7,8-dihydrodemethyl M6G (21) [6]

































































     pyranosyl bromide
LiOH
40% yield













































47a: R1=Ac; R2=COOMe (63%)
47b: R1=H; R2=COOMe (56%)
47c: R1=Me; R2=COOMe (77%)
47d: R1=Ac; R2=CH2OAc (74%)
47e: R1=H; R2=CH2OAc (15%)
47f : R1=Me; R2=CH2OAc (82%)
25a: R1=H; R2=COOH (54%)
25b: R1=Me; R2=COOH (79%)
25c: R1=H; R2=CH2OH (59%)
25d: R1=Me; R2=CH2OH (26%)
Scheme 12 Synthesis of M6G thiosaccharide analogues (25a–d) [4]
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Table 2 Pharmacological effects associated with opioid receptor types [20]
Sl. no. Pharmacological effects Opioid receptors
mu (l) Delta (d) Kappa (j)
1. Analgesia Supraspinal Supraspinal -
Spinal Spinal Spinal
2. Pupil constriction ?? ?? -
3. Respiratory depression ??? ?? ?
4. Diuresis Antidiuresis - ?
5. Gastrointestinal Constipation Constipation -
6. Smooth muscle Spasm Spasm -
7. Behavior/affect Euphoria - Dysphoria
Sedation - Sedation
8. Physical dependence ?? ?? ?
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H2, 10% Pd–C, MeOH, HCl 52%
Amide-linked C- -glycopyranoside




Scheme 13 Synthesis of amide-linked C-b-glycopyranoside analogue of M6G (27) [19]
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Ltd., Long Beach,
Calif.
Topical application of opioid drugs
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Process for extracting and
purifying morphine from opium










Morphine-6-glucuronide synthesis Parsons, P. J. and Ewin,
R. A.
[53]
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5 Conclusion
It may concluded from the above discussions that glyco-
sylation of the natural product, morphine (an anesthetic
drug) is responsible for the effective structural modification
for enhancing hydrophilicity of the compound—as a result
of which pharmacokinetic and/or pharmacodynamic prop-
erties are improved. In some cases, attachment of glycosyl
residue provides a new chemical entity (prodrug), which
facilitates the drug delivery in a more effective manner. A
significant number of related patents have also been filed so
far. Therefore, this review will be very much helpful for the
direction of searching new effective anesthetic drug con-
taining morphine skeleton in near future.
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